Pyrogastrone treatment of peptic oesophagitis: analysis of 104 patients treated during a 3 1/2-year period.
A retrospective analysis was carried out in 104 patients with peptic oesophagitis treated with Pyrogastrone (carbenoxolone with alginate-antacid) during a 3 1/2-year period. There wer 3 treatment groups: one had Pyrogastrone alone, another pyrogastrone with metoclopramide and in the third, both agents were given together with cimetidine. Highly significant symptomatic improvement was achieved in 85% of 96 patients treated between 4 and 8 weeks and equally significant endoscopic healing was noted in 76% of 55 patients for the same period. Best results were seen in those given Pyrogastrone alone; the concurrent use of metoclopramide and cimetidine did not enhance healing or symptom relief. 40% of patients received multiple courses, 22% were treated for at least six months and 16% for one year or longer continuously; 3 patients for over 3 years. The only noteworthy side effects were due to the tablet flavour and chewing property. These results confirm clinical trial experience that Pyrogastrone is highly effective in healing peptic esophagitis.
D000328:Adult; D000368:Aged; D000464:Alginates / Q000009:adverse effects / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000009:adverse effects / Q000627:therapeutic use*; D001639:Bicarbonates / Q000009:adverse effects / Q000627:therapeutic use*; D002229:Carbenoxolone / Q000009:adverse effects / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D004945:Esophagoscopy; D005260:Female; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies; D017640:Silicates; D012824:Silicic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D012822:Silicon Dioxide / Q000627:therapeutic use*
D000464:Alginates; D001639:Bicarbonates; D004338:Drug Combinations; D017640:Silicates; D012824:Silicic Acid; D000536:Aluminum Hydroxide; D012822:Silicon Dioxide; C021080:pyrogastrone; D002927:Cimetidine; D008787:Metoclopramide; D002229:Carbenoxolone; D006034:Glycyrrhetinic Acid